N/A N=5 Thalamic Deep Brain Stimulation for Secondary Dystonia in Children and Young Adults
Dystonia
Primary: Change From Baseline in Burke-Fahn-Marsden Dystonia Rating Scale — 14.7 change in points on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=42 Single Arm on the Tolerability of Weekly Nab-paclitaxel
Non Small Cell Lung Cancer (NSCLC)
Primary: Number of Subjects Without Any Adverse Events Grade 3 or Higher — 28 Participants
N/A N=24 Effect of Irvingia Gabonensis Administration on Metabolic Syndrome, Insulin Secretion and Insulin Sensitivity
Metabolic Syndrome X
Primary: Fasting Glucose Levels at Week 12 — 5.7; 5.9 mmol/L — p=0.240
N/A N=45 Progesterone for the Treatment of Cocaine Dependence - 1
Cocaine Abuse · Cocaine-Related Disorders
Primary: Decision to Self-Administer Cocaine — 66; 66; 32; 32 percent of available doses
Phase 3 N=638 Long-Term Safety and Tolerability Study of NKTR-181 in Subjects With Chronic Low Back Pain or Chronic Non-Cancer Pain
Low Back Pain · Chronic Pain
Primary: Number of Participants Reporting Adverse Events — 138; 151; 110; 62 Participants
N/A N=82 Cytokine Expression During Radiation for Breast Cancer
Breast Cancer
Primary: Number of Proteins Expressed Differently in Response to Receiving Radiation Therapy — 31 Proteins
N/A N=66 "Laparoscopic" Cystoscopy Versus Traditional Cystoscopy
Lower Urinary Tract Injury
Primary: Time Required to Perform Procedure (in Seconds) — 137; 451 seconds
Phase 1 N=23 Study to Evaluate Safety, Pharmacokinetics, and Antiviral Activity of Bictegravir (GS-9883) in Human Immunodeficiency Virus (HIV)-1 Infected Participants
HIV-1 Infection
Primary: Time-Weighted Average Change From Baseline up to Day 11 (DAVG11) in Plasma HIV-1 RNA — 4.26; 4.64; 4.42; 4.71 log10 copies/mL — p=<0.001
N/A N=444 Study of A New Contact Lens Cleaning and Disinfecting Solution
Vision Disorders
Primary: Percentage of Eyes With > Grade 2 Slit Lamp Findings — 4; 0 eyes
Phase 3 N=422 Effectiveness and Safety of EN3835 in the Treatment of Cellulite in Women
Edematous Fibrosclerotic Panniculopathy (Cellulite)
Primary: 2-level Composite Responders for the Target Buttock — 12; 1; 202; 205 Participants — p=0.002
Phase 3 N=952 Study to Evaluate the Safety and Efficacy of Two Adalimumab Dosing Regimens in Subjects With Moderate to Severe Ulcerative Colitis
Ulcerative Colitis (UC)
Primary: Induction Period Primary Endpoint: Percentage of Participants With Clinical Remission Per Full Mayo Score (FMS) at Week 8 — 10.9; 13.3; 11.6; 13.8 percentage of…
N/A N=567 A Product Performance Evaluation of a Novel Contact Lens for Daily Disposable Use
Myopia
Primary: Percentage of Participants With Favorable Responses for the Initial Lens Performance Survey — 340; 293; 326; 363 eyes
Phase 1 N=12 Safety and Pharmacokinetics of a Single Dose of CCH (3.36 mg) in Subjects With EFP
Edematous Fibrosclerotic Panniculopathy
Primary: Plasma AUX-I and AUX-II Concentrations — NA mmol/L
Phase 3 N=62 A Trial to Evaluate the Safety of Once Weekly Dosing of Somapacitan (NNC0195-0092) and Daily Norditropin® FlexPro® for 52 Weeks in Previously Human Growth Hormone Treated Japanese Adults With Growth Hormone Deficiency
Growth Hormone Disorder · Adult Growth Hormone Deficiency
Primary: Incidence of Adverse Events, Including Injection Site Reactions — 309.8; 312.7 Event rate per 100 patient years
Phase 1 N=13 Assessment of Safety, Tolerability and Pharmacokinetics of Intravitreal Pegcetacoplan (APL-2) for Patients With Wet AMD
Neovascular Age-Related Macular Degeneration
Primary: Number of Subjects Who Experienced Ocular and Systemic Adverse Events (AEs), Including by Severity — 2; 2; 4; 1 Participants